瑞士-芬兰代谢减重手术结局评分在大型前瞻性登记队列中的外部验证
本研究利用荷兰与斯堪的纳维亚肥胖手术登记数据(21 603例)及建立评分用的合并RCT数据(457例),对SF-BARI Score进行外部验证。5年时登记队列与RCT队列平均评分无统计学显著差异(90.9 vs 89.1分;差值1.8,95%CI -1.0至4.7;P=0.212),评分分布相似。Roux-en-Y胃旁路术5年平均评分较袖状胃切除术高11.2分(95%CI 10.2至12.2;P<0.001)。
要点
- SF-BARI Score在大型登记队列中外部验证可行,5年评分与RCT队列无显著差异。
- 登记队列与RCT队列基线特征在性别、2型糖尿病、高血压、血脂异常、OSAS及SG比例上存在显著差异(P<0.001)。
- Roux-en-Y胃旁路术5年平均评分较袖状胃切除术高11.2分(95%CI 10.2至12.2;P<0.001)。
核心结论
- SF-BARI Score在登记队列中外部验证可行,支持标准化报告及不同治疗方式的比较。
研究设计与样本
- 外部验证研究,纳入荷兰肥胖治疗审计登记、瑞典和挪威斯堪的纳维亚肥胖手术登记以及建立评分用的合并RCT数据。
- 纳入2010年1月至2018年6月接受初次代谢减重手术、基线特征及1年和5年随访数据完整的患者。
- 登记队列21 603例,合并RCT队列457例。
主要发现
- 5年时登记队列与合并RCT队列平均SF-BARI Score分别为90.9分和89.1分,差值1.8(95%CI -1.0至4.7),P=0.212,评分分布相似。
- 基线特征存在统计学显著差异:男性20.9% vs 29.3%,2型糖尿病16.7% vs 33.9%,高血压30.4% vs 66.1%,血脂异常13.7% vs 46.5%,阻塞性睡眠呼吸暂停综合征12.0% vs 17.4%,袖状胃切除术比例21.0% vs 49.9%(P<0.001)。
- Roux-en-Y胃旁路术5年平均评分较袖状胃切除术高11.2分(95%CI 10.2至12.2),P<0.001。
临床怎么用
- SF-BARI Score可用于代谢减重手术结局的标准化报告和不同治疗方式的比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Swiss-Finnish Bariatric Metabolic Outcome Score (SF-BARI Score), based on merged data of two RCTs, is a composite endpoint designed to evaluate and categorize outcomes after metabolic bariatric surgery (MBS). The aim of this study was to externally validate the score using registry data. METHODS: Individual patient data were included from the Dutch Audit for Treatment of Obesity, the Scandinavian Obesity Surgery Registries (SOReg-Sweden and SOReg-Norway), and the merged RCT data used for establishing the SF-BARI Score. All patients undergoing primary MBS from January 2010 to June 2018, with complete baseline characteristics, as well as complete 1- and 5-year follow-up data, were included. The mean total score and distribution were compared between the combined registry and merged RCT data. RESULTS: There was no statistically significant difference in the mean SF-BARI Score between the registries (21 603 patients) and merged RCTs (457 patients) at 5 years (90.9 versus 89.1 points; difference = 1.8 (95% c.i. -1.0 to 4.7); P = 0.212), and the score distribution was similar. Statistically significant differences in baseline characteristics existed regarding sex (male 20.9% versus 29.3%), type 2 diabetes (16.7% versus 33.9%), hypertension (30.4% versus 66.1%), dyslipidaemia (13.7% versus 46.5%), obstructive sleep apnoea syndrome (12.0% versus 17.4%), and sleeve gastrectomy (SG) rate (21.0% versus 49.9%) (P < 0.001). The mean score estimate at 5 years in Roux-en-Y gastric bypass was 11.2 (95% c.i. 10.2 to 12.2) points higher compared with SG (P < 0.001). CONCLUSION: This study verified the feasibility of the SF-BARI Score, enabling standardized reporting and allowing for comparison of different treatment modalities.
引用
- Bruinsma FFE, Hurme S, Peterli R, et al. Validation of the Swiss-Finnish Bariatric Metabolic Outcome Score within a large prospective registry cohort. Br J Surg. 2025. PMID: 40448630. doi:10.1093/bjs/znaf106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。